{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:01:05Z","timestamp":1761919265831,"version":"3.37.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>B virus infection of humans results in high morbidity and mortality in as many as 80% of identified cases. The main objective of this study was to conduct a comparative analysis of conventional and experimental antiviral drug susceptibilities of B virus isolates from multiple macaque species and zoonotically infected humans. We used a plaque reduction assay to establish the effective inhibitory doses of acyclovir, ganciclovir, and vidarabine, as well as those of a group of experimental nucleoside analogs with known anti-herpes simplex virus activity. Four of the experimental drugs tested were 10- to 100-fold more potent inhibitors of B virus replication than conventional antiviral agents. Drug efficacies were similar for multiple B virus isolates tested, with variations within 2-fold of the median effective concentration (EC<jats:sub>50<\/jats:sub>) for each drug, and each EC<jats:sub>50<\/jats:sub>was considerably lower than those for B virus thymidine kinase (TK) mutants. We observed no differences in the viral TK amino acid sequence between B virus isolates from rhesus monkeys and those from human zoonoses. Differences in the TK protein sequence between cynomolgus and pigtail macaque B virus isolates did not affect drug sensitivity except in the case of one compound. Taken together, these data suggest that future B virus zoonoses will respond consistently to conventional antiviral treatment. Further, the considerably higher potency of FEAU (2\u2032-fluoro-5-ethyl-Ara-U) than of conventional antiviral drugs argues for its compassionate use in advanced human B virus infections.<\/jats:p>","DOI":"10.1128\/aac.01435-08","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T01:06:54Z","timestamp":1256605614000},"page":"452-459","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of B Virus (<i>Macacine herpesvirus<\/i>1) by Conventional and Experimental Antiviral Compounds"],"prefix":"10.1128","volume":"54","author":[{"given":"P. W.","family":"Krug","sequence":"first","affiliation":[{"name":"Viral Immunology Center, Georgia State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. F.","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. K.","family":"Hilliard","sequence":"additional","affiliation":[{"name":"Viral Immunology Center, Georgia State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00170857","volume":"7","year":"1989","unstructured":"Abbruzzese, J. L., S. Schmidt, M. N. Raber, J. K. Levy, A. M. Castellanos, S. S. Legha, and I. H. Krakoff. 1989. Phase I trial of 1-(2\u2032-deoxy-2\u2032-fluoro-1-beta-d-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest. New Drugs7:195-201.","journal-title":"Invest. New Drugs"},{"key":"e_1_3_2_3_2","first-page":"526","volume":"44","year":"1994","unstructured":"Anderson, D. C., R. B. Swenson, J. L. Orkin, S. S. Kalter, and H. M. McClure. 1994. Primary Herpesvirus simiae (B-virus) infection in infant macaques. Lab. Anim. Sci.44:526-530.","journal-title":"Lab. Anim. Sci."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/13.2.288"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)80855-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.suppl_A.107"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6215.681"},{"key":"e_1_3_2_8_2","first-page":"453","volume":"38","year":"1989","unstructured":"Centers for Disease Control. 1989. B virus infections in humans\u2014Michigan. MMWR Morb. Mortal. Wkly. Rep.38:453-454.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_9_2","first-page":"289","volume":"36","year":"1987","unstructured":"Centers for Disease Control. 1987. B-virus infection in humans\u2014Pensacola, Florida. MMWR Morb. Mortal. Wkly. Rep.36:289-290, 295-296.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_10_2","first-page":"1073","volume":"47","year":"1998","unstructured":"Centers for Disease Control and Prevention. 1998. Fatal Cercopithecine herpesvirus 1 (B virus) infection following a mucocutaneous exposure and interim recommendations for worker protection. MMWR Morb. Mortal. Wkly. Rep.47:1073-1076, 1083.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_11_2","first-page":"96","volume":"44","year":"1995","unstructured":"Centers for Disease Control and Prevention. 1995. Publication of guidelines for the prevention and treatment of B virus infections in exposed persons. MMWR Morb. Mortal. Wkly. Rep.44:96-97.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.9.1355"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.1.33"},{"key":"e_1_3_2_14_2","first-page":"55","volume":"69","year":"1985","unstructured":"Fanucchi, M. P., B. Leyland-Jones, C. W. Young, J. H. Burchenal, K. A. Watanabe, and J. J. Fox. 1985. Phase I trial of 1-(2\u2032-deoxy-2\u2032-fluoro-1-beta-d-arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat. Rep.69:55-59.","journal-title":"Cancer Treat. Rep."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01284-06"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.2.421"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-11-833"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(88)90028-9"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2460\/javma.1981.179.11.1236","volume":"179","year":"1981","unstructured":"Loomis, M. R., T. O'Neill, M. Bush, and R. J. Montali. 1981. Fatal herpesvirus infection in patas monkeys and a black and white colobus monkey. J. Am. Vet. Med. Assoc.179:1236-1239.","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00388a021"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1990.01070070099044"},{"key":"e_1_3_2_22_2","first-page":"555","volume":"52","year":"2002","unstructured":"Ohsawa, K., D. H. Black, R. Torii, H. Sato, and R. Eberle. 2002. Detection of a unique genotype of monkey B virus (Cercopithecine herpesvirus 1) indigenous to native Japanese macaques (Macaca fuscata). Comp. Med.52:555-559.","journal-title":"Comp. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.1987.tb00322.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.53.2.587-595.1985"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)47263-3"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.9224-9232.1998"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(90)90035-6"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00572959"},{"key":"e_1_3_2_29_2","first-page":"157","volume":"17","year":"1992","unstructured":"Trousdale, M. D., J. L. Law, F. A. Yarber, K. A. Watanabe, and J. J. Fox. 1992. Evaluation of 1-(2\u2032-deoxy-2\u2032-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil in a rabbit model of herpetic keratitis. Antiviral Res.17:157-167.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_30_2","unstructured":"U.S. Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention and National Institutes of Health. 2007. Biosafety in microbiological and biomedical laboratories 5th ed. Government Printing Office Washington DC. http:\/\/www.cdc.gov\/OD\/OHS\/biosfty\/bmbl5\/BMBL_5th_Edition.pdf ."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03320150051031"},{"key":"e_1_3_2_32_2","first-page":"485","volume":"56","year":"1975","unstructured":"Vizoso, A. D. 1975. Recovery of herpes simiae (B virus) from both primary and latent infections in rhesus monkeys. Br. J. Exp. Pathol.56:485-488.","journal-title":"Br. J. Exp. Pathol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-1702(89)90044-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00187a005"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.2.555"},{"key":"e_1_3_2_36_2","first-page":"109","volume":"16","year":"1981","unstructured":"Whitley, R. J., and C. A. Alford. 1981. Antiviral agents: clinical status report. Hosp. Pract. (Off. Ed.)16:109-121.","journal-title":"Hosp. Pract. (Off. Ed.)"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560061005"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/104063879000200321"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1258\/002367784780864929"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(89)90037-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01435-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01435-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T22:48:52Z","timestamp":1739400532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01435-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1128\/AAC.01435-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01435-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"2008-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}